Immunotherapy in Triple-Negative Breast Cancer

PROGRAM DESCRIPTION Triple negative breast cancer (TNBC) is a biologically heterogeneous disease that accounts for about 15% of all breast cancers. Unlike luminal breast tumors, TNBC does not express a ...

PROGRAM DESCRIPTION
Triple negative breast cancer (TNBC) is a biologically heterogeneous disease that accounts for about 15% of all breast cancers. Unlike luminal breast tumors, TNBC does not express a prototypical target for therapy that has been clinically validated. Therefore, chemotherapy is the mainstay of systemic therapy for both early and late-stage TNBC. Monoclonal antibody antagonists specific for programmed death-1 (PD-1) receptor or its ligand programmed death ligand-1 (PD-L1) have now been approved for multiple solid tumors and emerging data suggest that these agents will likely play a role in the clinical management of patients with TNBC as well. This activity will review data describing the clinical activity of inhibitors specific for the PD-1/PD-L1 pathway, discuss the management considerations unique to immunotherapy relative to standard chemotherapy, and highlight future directions to enhance the activity of immunotherapy for patients with TNBC.

EDUCATIONAL OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:DESCRIBE the rationale for harnessing the immune system to treat TNBC.EVALUATE the efficacy and safety of late-stage clinical research immunotherapeutic agents for TNBC.REVIEW potential current and future clinical practice implications of immunotherapeutic agents in the treatment of TNBC.The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

---

Write the first review

Resource tags